Advertisement


Julie Côté, MD, on Multiple Myeloma: Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients

2022 ASH Annual Meeting and Exposition

Advertisement

Julie Côté, MD, of CHU de Québec–Université Laval, discusses findings from the Canadian Myeloma Research Group database, which showed that integrating bortezomib and lenalidomide into the autologous stem cell transplant (ASCT) sequence produces a median overall survival rate ≥ 10 years in most patients with newly diagnosed multiple myeloma. These observations highlight the contribution of post-ASCT maintenance, particularly lenalidomide given until disease progression, when used in multiple patient groups including those with and without high risk, as well as those requiring a second induction regimen (Abstract 117).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The standard of care for multiple myeloma patients with a new diagnosis and for patients that are transplant eligible in Canada, is to first to start with a bortezomib-based induction and then go with a high dose melphalan, an autologous stem cell transplant, followed by lenalidomide maintenance until progression. So, the aim of our study was really to look at the outcomes in details of this patient population in Canada, in the real world setting. So, using our national myeloma database from the C M R G, known as the Canadian Myeloma Research Group, all the patients who received an autologous stem cell transplant for multiple myeloma in the first line setting, from January 2007 to December 2021, were included. So, this gives us 3,800 patients approximately, and most of them received a bortezomib-based induction, mostly being CYBORD, in 72%. We had mostly single-transplant patients. Only 8% received tandem transplant, and it was mostly in high risk patients. 18% of the population were high risk. And what's interesting to see is that, overall with one single transplant, median PFS was around 35 months, and median overall survival was around 10 years. And median overall survival was around 10 years for approximately all subgroup patients, except in high-risk patients; so high-risk patients had inferior outcomes. For consolidation therapy, it's not root routinely available in Canada, so only a few patients received that kind of therapy, about 5%. It was mostly a regimen combining a ubiquitin and a proteasome inhibitor. Globally, consolidation leads to a better PFS, but with no significant gain on OS. For maintenance therapy, about half of our court received maintenance therapy, and it was mostly lenalidomide-based regimen. Maintenance therapy was leading to a significant benefit on PFS and OS, in all risk subgroups, although it does not completely abrogate the negative impact of high risk cytogenetics in the high risk patients. Globally, with the lenalidomide-based maintenance regimen, the PFS was around 4.5 years, and the overall survival around 13 years. As you can see, this real world data covers about 15 years in our court of timeline. And it really shows that the integration of bortezomib and lenalidomide in the transplant sequence, leads to an overall survival of about 10 years in most autologous stem cell transplant patient. It also highlights the beneficial contribution of lenalidomide mainstream therapy in patients without and with high risks, and also in patients receiving a second course of induction. Indeed, these patients had significantly inferior outcomes compared to those receiving only one induction regimen, but with maintenance therapy, outcomes would were comparable even though you received one or two induction regimen. So, this really highlights the importance of maintenance therapy in these subgroups. Right now, further analysis are ongoing, to look at relationship between treatment outcomes, patients characteristics, and these results will really serve as Canadian benchmarks to compare with newer approaches that are eventually coming.

Related Videos

Lymphoma

Jia Ruan, MD, PhD, on Mantle Cell Lymphoma: Phase II Findings on Acalabrutinib/Lenalidomide/Rituximab

Jia Ruan, MD, PhD, of Meyer Cancer Center, Weill Cornell Medicine, and NewYork-Presbyterian Hospital, discusses trial results demonstrating that the triple chemotherapy-free combination of acalabrutinib, lenalidomide, and rituximab is well tolerated, highly effective, and produces high rates of minimal residual disease (MRD)-negative complete response as an initial treatment for patients with mantle cell lymphoma, including those with TP53 mutations. Real-time MRD analysis may enable treatment de-escalation during maintenance to minimize toxicity, which warrants further evaluation. An expansion cohort of acalabrutinib/lenalidomide/obinutuzumab is being launched (Abstract 73).

Lymphoma
Immunotherapy

Tycel J. Phillips, MD, on Mantle Cell Lymphoma: New Findings on Glofitamab Monotherapy

Tycel J. Phillips, MD, of the City of Hope National Medical Center, discusses data that showed fixed-duration glofitamab monotherapy induced high and durable complete response rates in patients with mantle cell lymphoma (MCL) who received obinutuzumab pretreatment. This is one of the largest data sets and longest follow-ups reported with a CD20/CD3 bispecific monoclonal antibody for patients with relapsed or refractory MCL (Abstract 74).

Multiple Myeloma
Genomics/Genetics
Immunotherapy

Francesco Maura, MD, on Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated With Targeted Immunotherapy

Francesco Maura, MD, of the University of Miami, Sylvester Comprehensive Cancer Center, discusses his team’s findings in which they defined a comprehensive catalogue of genomic determinants of response to DKRd (carfilzomib, lenalidomide, dexamethasone) in newly diagnosed multiple myeloma. The researchers have identified a number of new genomic alterations that explain resistance to the agents currently used in combination regimens (Abstract 470).

 

Lymphoma

Kathryn R. Tringale, MD, on Primary CNS Lymphoma: Initial Treatment Response in More Than 500 Patients

Kathryn R. Tringale, MD, of Memorial Sloan Kettering Cancer Center, discusses an assessment of 559 patients with primary central nervous system (CNS) lymphoma and the factors associated with consolidation therapy selection, outcomes after consolidation therapy accounting for patient factors, and patterns of disease failure. The initial treatment response was prognostic and predictive of relapse patterns (Abstract 557).

Multiple Myeloma
Immunotherapy

Eileen M. Boyle, MD, PhD, on Multiple Myeloma: Sustained MRD Negativity in Newly Diagnosed Disease Treated with Immunotherapy Regimens

Eileen M. Boyle, MD, PhD, of the Perlmutter Cancer Center, NYU Langone Health, discusses Fc-mediated antibody effector function, inflammation resolution, and oligoclonality and their role in predicting sustained measurable residual disease negativity in patients with newly diagnosed multiple myeloma who were treated with immunotherapy regimens. For the first time, an analysis of T-cell receptors shows that oligoclonal profiles seen on treatment may influence the fitness of the immune response (Abstract 100).

Advertisement

Advertisement




Advertisement